Video

Dr. Villaruz on Selecting Between Single-Agent and Combination Immunotherapy in NSCLC

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

Liza C. Villaruz, MD, associate professor of medicine, medical oncologist, Division of Hematology/Oncology, UPMC Hillman Cancer Center, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer (NSCLC).

Several single-agent and combination immunotherapy regimens, such as nivolumab (Opdivo) plus ipilimumab (Yervoy), are approved for use in patients with NSCLC based on PD-L1 status, Villaruz explains. Additionally, some chemoimmunotherapy combinations are approved irrespective of PD-L1 status.

Patients with PD-L1–high NSCLC by tumor proportion score (TPS) of 50% or higher are typically treated with single-agent immunotherapy with pembrolizumab (Keytruda) or cemiplimab-rwlc (Libtayo), Villaruz says. Although single-agent pembrolizumab is also approved for patients with PD-L1 TPS of 1% or greater, it is important to note that this group has more variable responses to single-agent immunotherapy that are not as pronounced compared with those in the PD-L1–high population.

As such, patients with a PD-L1 status of 1% to 49% should be considered for combination chemoimmunotherapy. For symptom control, chemoimmunotherapy should also be considered for patients with PD-L1–high NSCLC who have significant tumor burden to potentially elicit an early cytoreductive effect, Villaruz concludes.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD